[HTML][HTML] Culture-negative periprosthetic joint infection: an update on what to expect
TL Tan, MM Kheir, N Shohat, DD Tan, M Kheir… - JBJS Open …, 2018 - journals.lww.com
Background: Culture-negative periprosthetic joint infection (PJI) is a challenging condition to
treat. The most appropriate management of culture-negative PJI is not known, and there is …
treat. The most appropriate management of culture-negative PJI is not known, and there is …
[HTML][HTML] Vancomycin prophylaxis for total joint arthroplasty: incorrectly dosed and has a higher rate of periprosthetic infection than cefazolin
Background In total joint arthroplasty (TJA), vancomycin is used as perioperative antibiotic
prophylaxis in patients with penicillin allergy or in patients colonized with methicillin-resistant …
prophylaxis in patients with penicillin allergy or in patients colonized with methicillin-resistant …
Polymicrobial periprosthetic joint infections: outcome of treatment and identification of risk factors
Background: The treatment outcomes of periprosthetic joint infection are frequently dependent
on characteristics of the causative organism. The objective of this comparative study was …
on characteristics of the causative organism. The objective of this comparative study was …
Diagnosing periprosthetic joint infection: and the winner is?
Background Diagnosis of periprosthetic joint infection (PJI) remains a challenge despite a
wide variety of available diagnostic tests. The question that arises is which of these tests has a …
wide variety of available diagnostic tests. The question that arises is which of these tests has a …
[HTML][HTML] Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
…, M Colamonici, W Palivos, PA Atsaves, D Tan… - Nature …, 2022 - nature.com
Interferons (IFNs) are key initiators and effectors of the immune response against malignant
cells and also directly inhibit tumor growth. IFNα is highly effective in the treatment of …
cells and also directly inhibit tumor growth. IFNα is highly effective in the treatment of …
Chronic kidney disease linearly predicts outcomes after elective total joint arthroplasty
TL Tan, MM Kheir, DD Tan, EJ Filippone… - The Journal of …, 2016 - Elsevier
Background Kidney disease is associated with increased complications in total joint
arthroplasty (TJA). The purpose of this study was to determine the association of kidney disease …
arthroplasty (TJA). The purpose of this study was to determine the association of kidney disease …
Proliferation saturation index in an adaptive Bayesian approach to predict patient-specific radiotherapy responses
ED Sunassee, D Tan, N Ji, R Brady… - … journal of radiation …, 2019 - Taylor & Francis
… Dean Tan Dean Tan, was a HIP IMO high school intern in the Integrated Mathematical
Oncology department at Moffitt Cancer Center when he contributed to this study, and is currently a …
Oncology department at Moffitt Cancer Center when he contributed to this study, and is currently a …
[PDF][PDF] Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or …
Background Homozygosity at HLA-I locus has been reported to be an unfavorable predictive
biomarker of second-line or beyond immunotherapy in patients with different types of cancer…
biomarker of second-line or beyond immunotherapy in patients with different types of cancer…
[HTML][HTML] Differentiation Syndrome in a Patient With Non-Small Cell Lung Cancer (NSCLC) Harboring IDH2 Mutation Treated With Enasidenib: Case Report
B Sukhadia, D Tan, Y Oh, Z Shah, YK Chae - JTO Clinical and Research …, 2023 - Elsevier
IDH2 gain-of-function mutations cause DNA hypermethylation interfering with cellular
differentiation, and are linked to poor disease outcomes in NSCLC. IDH2-inhibitor enasidenib is …
differentiation, and are linked to poor disease outcomes in NSCLC. IDH2-inhibitor enasidenib is …
Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line …
Background Homozygosity at HLA-I locus has been reported to be an unfavorable predictive
biomarker of second-line or beyond immunotherapy in patients with different types of cancer…
biomarker of second-line or beyond immunotherapy in patients with different types of cancer…